ACTG A5186

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5186 is a phase II, randomized, open-label, multi-site trial to determine the efficacy and safety of fish oil combined with fenofibrate in HIV-infected subjects on highly active antiretroviral therapy (HAART) with elevated serum triglycerides (TG) who are not responding to either agent alone. Primary Objectives: To evaluate the safety and tolerability of fish oil supplement alone or in combination with Fenofibrate in an HIV-infected population with elevated serum TG.To evaluate whether the combination of fish oil supplement and Fenofibrate will decrease serum triglycerides (TG) to 3200 mg/dL in subjects not responding to either agent alone